Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China flag China · Delayed Price · Currency is CNY
5.55
-0.25 (-4.31%)
Nov 6, 2026, 3:00 PM CST

SHA:600664 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
16,23215,90116,11915,40013,75512,741
Other Revenue
63.2463.2456.8356.2153.6361.06
16,29515,96416,17615,45713,80912,802
Revenue Growth
2.22%-1.31%4.65%11.93%7.86%18.66%
Cost of Revenue
12,07211,85011,65511,44310,4469,826
Gross Profit
4,2234,1144,5214,0133,3632,976
Selling, General & Admin
3,0633,2203,3903,1432,5652,306
Research & Development
143.16145.01136.43106.02115.8197.73
Other Operating Expenses
141.57112.43108.29120.17122.65113.17
Operating Expenses
3,3833,5423,6713,3952,8052,528
Operating Income
840.46572.25849.71618.44557.91447.79
Interest Expense
-37.39-42.55-60.07-56.47-85.53-105.16
Interest & Investment Income
17.9124.3549.4751.5869.1916.5
Currency Exchange Gain (Loss)
-4.4-4.4-5.68-5.3731.99
Other Non Operating Income (Expenses)
-26.15-30.5266.61-22.74-19.44-5.07
EBT Excluding Unusual Items
790.43519.13900.04585.45525.13356.06
Gain (Loss) on Sale of Investments
-0.77-0.77---20-
Gain (Loss) on Sale of Assets
35.623.520.940.98161.38210.87
Asset Writedown
-1.8-2.59-59.84-15.13-32.52-2.33
Other Unusual Items
49.9253.4533.8779.2567.1765.93
Pretax Income
873.4572.74875.01650.54701.15630.53
Income Tax Expense
197.07173.96184.4176.32188.94220.69
Earnings From Continuing Operations
676.33398.78690.61474.22512.21409.85
Minority Interest in Earnings
-43.1-37.18-61.76-78.95-47.06-38.76
Net Income
633.23361.6628.85395.26465.15371.08
Net Income to Common
633.23361.6628.85395.26465.15371.08
Net Income Growth
40.98%-42.50%59.10%-15.02%25.35%-
Shares Outstanding (Basic)
2,5632,5832,5152,4702,4482,474
Shares Outstanding (Diluted)
2,5632,5832,5152,4702,5842,474
Shares Change
2.31%2.68%1.82%-4.40%4.46%-1.29%
EPS (Basic)
0.250.140.250.160.190.15
EPS (Diluted)
0.250.140.250.160.180.15
EPS Growth
37.81%-44.00%56.25%-11.11%20.00%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
723.47288.71691.69863.14532.45-239.13
Free Cash Flow Per Share
0.280.110.280.350.21-0.10
Gross Margin
25.92%25.77%27.95%25.96%24.35%23.24%
Operating Margin
5.16%3.58%5.25%4.00%4.04%3.50%
Profit Margin
3.89%2.27%3.89%2.56%3.37%2.90%
Free Cash Flow Margin
4.44%1.81%4.28%5.58%3.86%-1.87%
EBITDA
1,040789.311,090878.27821.32716.99
EBITDA Margin
6.38%4.94%6.74%5.68%5.95%5.60%
D&A For EBITDA
199.28217.06240.76259.83263.41269.2
EBIT
840.46572.25849.71618.44557.91447.79
EBIT Margin
5.16%3.58%5.25%4.00%4.04%3.50%
Effective Tax Rate
22.56%30.37%21.07%27.10%26.95%35.00%
Revenue as Reported
16,29515,96416,17615,45713,80912,802
Advertising Expenses
-1,5961,8061,5741,058340.89